Featured Research

from universities, journals, and other organizations

New Hope For Arthritis Patients: Fighting Inflammation With Targeted Liposomal Therapy

Date:
March 29, 2006
Source:
John Wiley & Sons, Inc.
Summary:
The results of a recent study indicate the promise of targeted liposomal therapy for rheumatoid arthritis patients.

Vascular endothelial cells (VECs) form the walls of blood vessels and play a critical role in inflammation. In rheumatoid arthritis (RA), VECs interact with cytokines, proteins that regulate immune response, and allow inflammation to persist, escalate, and progressively damage tissue, and joints. Recognized as potent inflammation inhibitors, corticosteroids work to control the expression of cytokines, adhesion molecules and the growth of endothelial cells. The potential of these drugs, however, has been restricted by their considerable toxicity and short half-life.

Related Articles


To study the impact of corticosteroids on VEC activity, researchers in The Netherlands turned to liposomes, microscopic vesicles used to deliver drugs or genetic material directly into a cell. They chose RGD peptide liposomes to deliver a dose of dexamethasone phosphate (DEXP) to VECs at the site of inflammation in rats with experimental arthritis. The results, presented in the April 2006 issue of Arthritis & Rheumatism indicate the promise of targeted liposomal therapy for rheumatoid arthritis patients.

RGD peptide was selected for targeting of the liposomes based on its high chemical stability and its high affinity for proteins expressed on angiogenic VECs At sties of inflammation. To create a disease sample, rats with adjuvant-induced arthritis (AIA) and rats or mice were injected with a lipopolysaccharide (LPS)-induced inflammation were used. After disease onset, generally 12 days after the inductions, the rats were randomly divided to receive treatment. One group received a single intravenous injection of 1 milligram of DEXP encapsulated in targeted RGD peptide-exposing polyethylene glycol liposomes (RGD-PEG-L). Another group was injected with the same dosage of DEXP encapsulated in non-targeted PEG liposomes. A control group was injected with an empty liposomes. To allow examination of liposome interactions with blood vessel walls in living animals, researchers used a mouse dorsal skin flap window model and distinguished RGD-PEG liposomes by fluorescent labels.

One hour after injection of the liposomes, which was performed only four hours after the induction of the inflammation, researchers observed strong binding of the RGD-PEG liposomes to the blood vessel wall at the site of the inflammation. Besides their rapid attack on VEC activity, the binding of RGD-PEG liposomes to inflamed sites was three-fold higher than that of the liposomes without the peptide.

Disease activity and its toll were monitored among the rats with AIA. Arthritis severity was scored by grading each paw from 0 to 4, based on redness, swelling, and joint immobility, with a maximum possible score of 16 per animal. Rats treated with DEXP-containing RGD-PEG liposomes showed the lowest overall scores, the strongest anti-inflammatory effects, and delayed disease progression.

This study demonstrates the potential of corticosteroid-carrying, VEC-binding RGD liposomes to quickly relieve inflammation and significantly reduce its ravages. "Using these liposomes to deliver DEXP to VECs at sites of arthritis involvement proved very efficacious in rat AIA, indicating promise for the treatment of rheumatoid arthritis," note the study's leading authors, Gert Storm, Ph.D. and Gerben Koning, Ph.D. "Future research will focus more precisely on the mechanisms involved and may also explore delivery of other anti-inflammatory compounds by the RGD-targeted liposomes."

Article: "Targeting of Angiogenic Endothelial Cells at Sites of Inflammation by Dexamethasone Phosphate-Containing RGD Peptide Liposomes Inhibits Experimental Arthritis," Gerben A. Koning, Raymond M. Schiffelers, Marca H. M. Wauben, Robber J. Kok, Enrico Mastrobattista, Grietje Molema, Timo L. M. ten Hagen, and Gert Storm, Arthritis & Rheumatism, April 2006, 54:4, pp. 1198-1208.


Story Source:

The above story is based on materials provided by John Wiley & Sons, Inc.. Note: Materials may be edited for content and length.


Cite This Page:

John Wiley & Sons, Inc.. "New Hope For Arthritis Patients: Fighting Inflammation With Targeted Liposomal Therapy." ScienceDaily. ScienceDaily, 29 March 2006. <www.sciencedaily.com/releases/2006/03/060329083600.htm>.
John Wiley & Sons, Inc.. (2006, March 29). New Hope For Arthritis Patients: Fighting Inflammation With Targeted Liposomal Therapy. ScienceDaily. Retrieved November 24, 2014 from www.sciencedaily.com/releases/2006/03/060329083600.htm
John Wiley & Sons, Inc.. "New Hope For Arthritis Patients: Fighting Inflammation With Targeted Liposomal Therapy." ScienceDaily. www.sciencedaily.com/releases/2006/03/060329083600.htm (accessed November 24, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, November 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola-Hit Sierra Leone's Late Cocoa Leaves Bitter Taste

Ebola-Hit Sierra Leone's Late Cocoa Leaves Bitter Taste

AFP (Nov. 23, 2014) The arable district of Kenema in Sierra Leone -- at the centre of the Ebola outbreak in May -- has been under quarantine for three months as the cocoa harvest comes in. Duration: 01:32 Video provided by AFP
Powered by NewsLook.com
Don't Fall For Flu Shot Myths

Don't Fall For Flu Shot Myths

Newsy (Nov. 23, 2014) Misconceptions abound when it comes to your annual flu shot. Medical experts say most people older than 6 months should get the shot. Video provided by Newsy
Powered by NewsLook.com
WFP: Ebola Risks Heightened Among Women Throughout Africa

WFP: Ebola Risks Heightened Among Women Throughout Africa

AFP (Nov. 21, 2014) Having children has always been a frightening prospect in Sierra Leone, the world's most dangerous place to give birth, but Ebola has presented an alarming new threat for expectant mothers. Duration: 00:37 Video provided by AFP
Powered by NewsLook.com
Could Your Genes Be The Reason You're Single?

Could Your Genes Be The Reason You're Single?

Newsy (Nov. 21, 2014) Researchers in Beijing discovered a gene called 5-HTA1, and carriers are reportedly 20 percent more likely to be single. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins